Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole in Pediatric Subjects With Symptomatic Nonerosive GERD
NCT02616302Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Takeda. Primary endpoint: Percentage of Days Without Hurting or Burning in the Stomach, Chest or Throat at 12 weeks. Started Feb 2023; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02616302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616302.